Harvard Bioscience is counting on huge returns from its Asia strategy where it plans to partner with Chinese companies and expand its distribution, says the scientific instrument-seller's CEO Jeff Duchemin. Duchemin says the company has gone through a major transformation after spinning off its regenerative technology unit last year, plus he says the harsh winter hampered sales in the first quarter. He says the company is now moving forward, especially in China, where he says the company is well positioned against traditional competitors like Thermo Fisher as well as smaller ones that continue to pop up.

If you liked this article you might like

Harvard Bioscience an 'Asymmetrical Long Shot'

Insider Trading Alert - HBIO, OFG And AVGO Traded By Insiders

Insider Trading Alert - TINY, CALD And HBIO Traded By Insiders

Insider Trading Alert - HBIO, NSH And BIOA Traded By Insiders

Harvard Bioscience Inc. Stock Downgraded (HBIO)